{"transactions":[{"id":1124278,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance Stock Option (right to buy)","published_at":"2025-06-03T20:00:35.000Z","date":"2025-05-31","kind":"grant","planned":false,"acquired":true,"shares":72000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 120,000 shares of common stock. The option vested based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Company certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 38,400 shares of common stock. On May 31, 2025, the Compensation Committee of the Board of Directors of the Company certified that the performance metrics related to the successful results of the CORAL trial were satisfied, resulting in the vesting of the option as to 72,000 shares of common stock."}],"balance_after":110400,"derivative":{"exercise_price":2.38,"exercise_date":"2025-05-31","expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":72000},"source":{"system":"sec-edgar","filing":"0000950170-25-080886","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025080886/ownership.xml","form_type":"4"}},{"id":1209180,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance Stock Option (right to buy)","published_at":"2025-03-12T20:00:09.000Z","date":"2025-03-10","kind":"grant","planned":false,"acquired":true,"shares":38400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 120,000 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Issuer certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 38,400 shares of common stock. The performance-based stock option remains eligible for vesting with respect to additional shares of common stock underlying the option in the event that performance metrics related to the successful results of the CORAL trial are satisfied."}],"balance_after":38400,"derivative":{"exercise_price":2.38,"exercise_date":"2025-03-10","expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":38400},"source":{"system":"sec-edgar","filing":"0000950170-25-037884","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025037884/ownership.xml","form_type":"4"}},{"id":1255141,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-20T21:00:05.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":225500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 18, 2025. The 225,500 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 18, 2026 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 18, 2029."}],"balance_after":225500,"derivative":{"exercise_price":4.22,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":225500},"source":{"system":"sec-edgar","filing":"0000950170-25-024111","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025024111/ownership.xml","form_type":"4"}},{"id":1304914,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-10T21:14:48.000Z","date":"2025-01-08","kind":"exercise","planned":false,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026."}],"balance_after":42125,"derivative":{"exercise_price":0.511,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000950170-25-004164","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025004164/ownership.xml","form_type":"4"}},{"id":1304913,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-10T21:14:48.000Z","date":"2025-01-07","kind":"exercise","planned":false,"acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026."}],"balance_after":47125,"derivative":{"exercise_price":0.511,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0000950170-25-004164","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025004164/ownership.xml","form_type":"4"}},{"id":1304912,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-10T21:14:48.000Z","date":"2025-01-08","kind":"exercise","planned":false,"acquired":true,"shares":5000,"price":0.511,"value":2555.0,"ownership":{"direct":true},"balance_after":64660,"source":{"system":"sec-edgar","filing":"0000950170-25-004164","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025004164/ownership.xml","form_type":"4"}},{"id":1304911,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-10T21:14:48.000Z","date":"2025-01-07","kind":"exercise","planned":false,"acquired":true,"shares":1000,"price":0.511,"value":511.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 5,381 shares purchased through the Issuer's employee stock purchase plan."}],"balance_after":59660,"source":{"system":"sec-edgar","filing":"0000950170-25-004164","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025004164/ownership.xml","form_type":"4"}},{"id":1501576,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-24T20:12:05.000Z","date":"2024-05-22","kind":"exercise","planned":false,"acquired":false,"shares":16043,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026."}],"balance_after":48125,"derivative":{"exercise_price":0.511,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":16043},"source":{"system":"sec-edgar","filing":"0000950170-24-064598","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017024064598/ownership.xml","form_type":"4"}},{"id":1501575,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-05-24T20:12:05.000Z","date":"2024-05-22","kind":"sale","planned":false,"acquired":false,"shares":4350,"price":2.6402,"value":11484.87,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale represents the sale of shares necessary to meet tax withholding obligations as a result of the exercise of stock options on May 22, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.64 to $2.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 5,685 shares purchased through the Issuer's employee stock purchase plan."}],"balance_after":53279,"source":{"system":"sec-edgar","filing":"0000950170-24-064598","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017024064598/ownership.xml","form_type":"4"}},{"id":1501574,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-05-24T20:12:05.000Z","date":"2024-05-22","kind":"exercise","planned":false,"acquired":true,"shares":16043,"price":0.511,"value":8197.973,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 5,685 shares purchased through the Issuer's employee stock purchase plan."}],"balance_after":57629,"source":{"system":"sec-edgar","filing":"0000950170-24-064598","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017024064598/ownership.xml","form_type":"4"}},{"id":1637594,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-16T21:42:03.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 15, 2024. The 175,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 15, 2025 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 15, 2028."}],"balance_after":175000,"derivative":{"exercise_price":2.38,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0000950170-24-016458","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017024016458/ownership.xml","form_type":"4"}},{"id":1760997,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-10-12T20:00:10.000Z","date":"2023-10-11","kind":"exercise","planned":true,"acquired":false,"shares":2292,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on October 13, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026."}],"balance_after":64168,"derivative":{"exercise_price":0.511,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":2292},"source":{"system":"sec-edgar","filing":"0001209191-23-052687","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123052687/doc4.xml","form_type":"4"}},{"id":1760996,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-10-12T20:00:10.000Z","date":"2023-10-11","kind":"sale","planned":true,"acquired":false,"shares":785,"price":2.02,"value":1585.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on October 13, 2022."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale represents the sale of shares necessary to meet tax withholding obligations as a result of the exercise of stock options on October 11, 2023."}],"balance_after":35901,"source":{"system":"sec-edgar","filing":"0001209191-23-052687","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123052687/doc4.xml","form_type":"4"}},{"id":1760995,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-10-12T20:00:10.000Z","date":"2023-10-11","kind":"exercise","planned":true,"acquired":true,"shares":2292,"price":0.511,"value":1171.212,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on October 13, 2022."}],"balance_after":36686,"source":{"system":"sec-edgar","filing":"0001209191-23-052687","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123052687/doc4.xml","form_type":"4"}},{"id":1781779,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-09-13T20:06:00.000Z","date":"2023-09-11","kind":"exercise","planned":true,"acquired":false,"shares":2291,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on October 13, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026."}],"balance_after":66460,"derivative":{"exercise_price":0.511,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":2291},"source":{"system":"sec-edgar","filing":"0001209191-23-049252","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123049252/doc4.xml","form_type":"4"}},{"id":1781778,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-09-13T20:06:00.000Z","date":"2023-09-11","kind":"sale","planned":true,"acquired":false,"shares":711,"price":2.2,"value":1564.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on October 13, 2022."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale represents the sale of shares necessary to meet tax withholding obligations as a result of the exercise of stock options on September 11, 2023."}],"balance_after":34394,"source":{"system":"sec-edgar","filing":"0001209191-23-049252","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123049252/doc4.xml","form_type":"4"}},{"id":1781777,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-09-13T20:06:00.000Z","date":"2023-09-11","kind":"exercise","planned":true,"acquired":true,"shares":2291,"price":0.511,"value":1170.701,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on October 13, 2022."}],"balance_after":35105,"source":{"system":"sec-edgar","filing":"0001209191-23-049252","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123049252/doc4.xml","form_type":"4"}},{"id":1808234,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-08-14T20:00:13.000Z","date":"2023-08-11","kind":"exercise","planned":true,"acquired":false,"shares":2292,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on October 13, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026."}],"balance_after":68751,"derivative":{"exercise_price":0.511,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":2292},"source":{"system":"sec-edgar","filing":"0001209191-23-045595","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123045595/doc4.xml","form_type":"4"}},{"id":1808233,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-08-14T20:00:13.000Z","date":"2023-08-11","kind":"sale","planned":true,"acquired":false,"shares":682,"price":2.36,"value":1609.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on October 13, 2022."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale represents the sale of shares necessary to meet tax withholding obligations as a result of the exercise of stock options on August 11, 2023."}],"balance_after":32814,"source":{"system":"sec-edgar","filing":"0001209191-23-045595","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123045595/doc4.xml","form_type":"4"}},{"id":1808232,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-08-14T20:00:13.000Z","date":"2023-08-11","kind":"exercise","planned":true,"acquired":true,"shares":2292,"price":0.511,"value":1171.212,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on October 13, 2022."}],"balance_after":33496,"source":{"system":"sec-edgar","filing":"0001209191-23-045595","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123045595/doc4.xml","form_type":"4"}},{"id":1830803,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-07-12T20:29:03.000Z","date":"2023-07-11","kind":"exercise","planned":true,"acquired":false,"shares":2292,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on October 13, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026."}],"balance_after":71043,"derivative":{"exercise_price":0.511,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":2292},"source":{"system":"sec-edgar","filing":"0001209191-23-042078","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123042078/doc4.xml","form_type":"4"}},{"id":1830802,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-07-12T20:29:03.000Z","date":"2023-07-11","kind":"sale","planned":true,"acquired":false,"shares":687,"price":2.34,"value":1607.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on October 13, 2022."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale represents the sale of shares necessary to meet tax withholding obligations as a result of the exercise of stock options on July 11, 2023."}],"balance_after":31204,"source":{"system":"sec-edgar","filing":"0001209191-23-042078","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123042078/doc4.xml","form_type":"4"}},{"id":1830801,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-07-12T20:29:03.000Z","date":"2023-07-11","kind":"exercise","planned":true,"acquired":true,"shares":2292,"price":0.511,"value":1171.212,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on October 13, 2022."}],"balance_after":31891,"source":{"system":"sec-edgar","filing":"0001209191-23-042078","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123042078/doc4.xml","form_type":"4"}},{"id":1855530,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-14T20:28:46.000Z","date":"2023-06-12","kind":"exercise","planned":true,"acquired":false,"shares":2291,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on October 13, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026."}],"balance_after":73335,"derivative":{"exercise_price":0.511,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":2291},"source":{"system":"sec-edgar","filing":"0001209191-23-037029","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123037029/doc4.xml","form_type":"4"}},{"id":1855529,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-06-14T20:28:46.000Z","date":"2023-06-12","kind":"sale","planned":true,"acquired":false,"shares":610,"price":2.64,"value":1610.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on October 13, 2022."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale represents the sale of shares necessary to meet tax withholding obligations as a result of the exercise of stock options on June 12, 2023."}],"balance_after":29599,"source":{"system":"sec-edgar","filing":"0001209191-23-037029","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123037029/doc4.xml","form_type":"4"}},{"id":1855528,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-06-14T20:28:46.000Z","date":"2023-06-12","kind":"exercise","planned":true,"acquired":true,"shares":2291,"price":0.511,"value":1170.701,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on October 13, 2022."}],"balance_after":30209,"source":{"system":"sec-edgar","filing":"0001209191-23-037029","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123037029/doc4.xml","form_type":"4"}},{"id":1893085,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-05-15T20:00:16.000Z","date":"2023-05-11","kind":"exercise","planned":true,"acquired":false,"shares":2291,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on October 13, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026."}],"balance_after":75626,"derivative":{"exercise_price":0.511,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":2291},"source":{"system":"sec-edgar","filing":"0001209191-23-029399","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123029399/doc4.xml","form_type":"4"}},{"id":1893084,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-05-15T20:00:16.000Z","date":"2023-05-11","kind":"sale","planned":true,"acquired":false,"shares":562,"price":2.89,"value":1624.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on October 13, 2022."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale represents the sale of shares necessary to meet tax withholding obligations as a result of the exercise of stock options on May 11, 2023."}],"balance_after":27918,"source":{"system":"sec-edgar","filing":"0001209191-23-029399","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123029399/doc4.xml","form_type":"4"}},{"id":1893083,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-05-15T20:00:16.000Z","date":"2023-05-11","kind":"exercise","planned":true,"acquired":true,"shares":2291,"price":0.511,"value":1170.701,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on October 13, 2022."}],"balance_after":28480,"source":{"system":"sec-edgar","filing":"0001209191-23-029399","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123029399/doc4.xml","form_type":"4"}},{"id":1920756,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-04-12T21:02:13.000Z","date":"2023-04-11","kind":"exercise","planned":true,"acquired":false,"shares":2292,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on October 13, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026."}],"balance_after":77917,"derivative":{"exercise_price":0.511,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":2292},"source":{"system":"sec-edgar","filing":"0001209191-23-024115","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123024115/doc4.xml","form_type":"4"}},{"id":1920755,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-04-12T21:02:13.000Z","date":"2023-04-11","kind":"sale","planned":true,"acquired":false,"shares":840,"price":1.839,"value":1544.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on October 13, 2022."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale represents the sale of shares necessary to meet tax withholding obligations as a result of the exercise of stock options on April 11, 2023."}],"balance_after":26189,"source":{"system":"sec-edgar","filing":"0001209191-23-024115","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123024115/doc4.xml","form_type":"4"}},{"id":1920754,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-04-12T21:02:13.000Z","date":"2023-04-11","kind":"exercise","planned":true,"acquired":true,"shares":2292,"price":0.511,"value":1171.212,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on October 13, 2022."}],"balance_after":27029,"source":{"system":"sec-edgar","filing":"0001209191-23-024115","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123024115/doc4.xml","form_type":"4"}},{"id":1951760,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-15T20:00:13.000Z","date":"2023-03-13","kind":"exercise","acquired":false,"shares":2291,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026."}],"balance_after":80209,"derivative":{"exercise_price":0.511,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":2291},"source":{"system":"sec-edgar","filing":"0001209191-23-018875","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123018875/doc4.xml","form_type":"4"}},{"id":1951759,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-15T20:00:13.000Z","date":"2023-03-13","kind":"sale","acquired":false,"shares":892,"price":1.7532,"value":1563.8544,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"kind","element":"transactionCoding","label":"F3","text":"This sale represents the sale of shares necessary to meet tax withholding obligations as a result of the exercise of stock options on March 13, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,312 shares purchased through the Issuer's employee stock purchase plan."}],"balance_after":24737,"source":{"system":"sec-edgar","filing":"0001209191-23-018875","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123018875/doc4.xml","form_type":"4"}},{"id":1951758,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-15T20:00:13.000Z","date":"2023-03-13","kind":"exercise","acquired":true,"shares":2291,"price":0.511,"value":1170.701,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,312 shares purchased through the Issuer's employee stock purchase plan."}],"balance_after":25629,"source":{"system":"sec-edgar","filing":"0001209191-23-018875","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123018875/doc4.xml","form_type":"4"}},{"id":2010498,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-16T22:18:03.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":187500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 16, 2023. The 187,500 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 16, 2024 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 16, 2027."}],"balance_after":187500,"derivative":{"exercise_price":2.67,"expiration_date":"2033-02-15","underlying":"Common Stock","underlying_shares":187500},"source":{"system":"sec-edgar","filing":"0001209191-23-010165","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123010165/doc4.xml","form_type":"4"}},{"id":2013214,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-15T21:01:34.000Z","date":"2023-02-13","kind":"exercise","acquired":false,"shares":27500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026."}],"balance_after":82500,"derivative":{"exercise_price":0.511,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":27500},"source":{"system":"sec-edgar","filing":"0001209191-23-009694","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123009694/doc4.xml","form_type":"4"}},{"id":2013213,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-02-15T21:01:34.000Z","date":"2023-02-13","kind":"sale","acquired":false,"shares":8474,"price":2.45,"value":20761.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Includes 4,312 shares purchased through the Issuer's employee stock purchase plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This sale represents the sale of shares necessary to meet tax withholding obligations as a result of the exercise of stock options on February 13, 2023."}],"balance_after":23338,"source":{"system":"sec-edgar","filing":"0001209191-23-009694","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123009694/doc4.xml","form_type":"4"}},{"id":2013212,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-02-15T21:01:34.000Z","date":"2023-02-13","kind":"exercise","acquired":true,"shares":27500,"price":0.511,"value":14052.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This sale represents the sale of shares necessary to meet tax withholding obligations as a result of the exercise of stock options on February 13, 2023."}],"balance_after":31812,"source":{"system":"sec-edgar","filing":"0001209191-23-009694","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919123009694/doc4.xml","form_type":"4"}},{"id":2393928,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-15T21:00:28.000Z","date":"2022-02-11","kind":"grant","acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 11, 2023 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026."}],"balance_after":110000,"derivative":{"exercise_price":0.511,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001209191-22-009738","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919122009738/doc4.xml","form_type":"4"}},{"id":2609759,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-08-09T21:34:03.000Z","date":"2021-08-09","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on August 9, 2021. The 100,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on August 9, 2022 and as to the remaining 75% of the shares in equal monthly installments thereafter, through August 9, 2025."}],"balance_after":100000,"derivative":{"exercise_price":1.97,"expiration_date":"2031-08-08","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-21-050440","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000120919121050440/doc4.xml","form_type":"4"}}]}